Literature DB >> 16528529

Screening of an annotated compound library for drug activity in a resistant myeloma cell line.

Linda Rickardson1, Mårten Fryknäs, Caroline Haglund, Henrik Lövborg, Peter Nygren, Mats G Gustafsson, Anders Isaksson, Rolf Larsson.   

Abstract

PURPOSE: Resistance to anticancer drugs is a major problem in chemotherapy. In order to identify drugs with selective cytotoxic activity in drug-resistant cancer cells, the annotated compound library LOPAC1280, containing compounds from 56 pharmacological classes, was screened in the myeloma cell line RPMI 8226 and its doxorubicin-resistant subline 8226/Dox40.
METHODS: Cell survival was measured by the Fluorometric Microculture Cytotoxicity Assay.
RESULTS: Selective cytotoxic activity in 8226/Dox40 was obtained for 33 compounds, with the most pronounced difference observed for the glucocorticoids. A microarray analysis of the cells showed a difference in mRNA-expression for the glucocorticoid receptor suggesting potential mechanisms for the difference in glucocorticoid sensitivity. In the presence of the glucocorticoid-receptor antagonist RU486, the sensitivity to the glucocorticoids was reduced and a similar effect level in RPMI 8226 and 8226/Dox40 was achieved.
CONCLUSION: In conclusion, screening of mechanistically annotated compounds on drug-resistant cancer cells can identify compounds with selective activity and provide a basis for the development of novel treatments of drug-resistant malignancies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528529     DOI: 10.1007/s00280-006-0216-7

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  An in vivo chemical library screen in Xenopus tadpoles reveals novel pathways involved in angiogenesis and lymphangiogenesis.

Authors:  Roland E Kälin; Nadja E Bänziger-Tobler; Michael Detmar; André W Brändli
Journal:  Blood       Date:  2009-05-28       Impact factor: 22.113

2.  Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

Authors:  Boyang Zhao; Joseph C Sedlak; Raja Srinivas; Pau Creixell; Justin R Pritchard; Bruce Tidor; Douglas A Lauffenburger; Michael T Hemann
Journal:  Cell       Date:  2016-02-25       Impact factor: 41.582

3.  Fluorescent RNA Aptamers as a Tool to Study RNA-Modifying Enzymes.

Authors:  Nina Svensen; Samie R Jaffrey
Journal:  Cell Chem Biol       Date:  2016-02-11       Impact factor: 8.116

Review 4.  Is resistance useless? Multidrug resistance and collateral sensitivity.

Authors:  Matthew D Hall; Misty D Handley; Michael M Gottesman
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

5.  The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.

Authors:  Malin Wickström; Caroline Haglund; Henrik Lindman; Peter Nygren; Rolf Larsson; Joachim Gullbo
Journal:  Invest New Drugs       Date:  2007-10-06       Impact factor: 3.850

6.  In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.

Authors:  Kristina Wiberg; Kristina Carlson; Anna Aleskog; Rolf Larsson; Peter Nygren; Elin Lindhagen
Journal:  Med Oncol       Date:  2008-11-18       Impact factor: 3.064

7.  Transcriptional regulation of oncogenic protein kinase Cϵ (PKCϵ) by STAT1 and Sp1 proteins.

Authors:  HongBin Wang; Alvaro Gutierrez-Uzquiza; Rachana Garg; Laura Barrio-Real; Mahlet B Abera; Cynthia Lopez-Haber; Cinthia Rosemblit; Huaisheng Lu; Martin Abba; Marcelo G Kazanietz
Journal:  J Biol Chem       Date:  2014-05-13       Impact factor: 5.157

8.  Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma.

Authors:  Badreddin Edris; Jonathan A Fletcher; Robert B West; Matt van de Rijn; Andrew H Beck
Journal:  Sarcoma       Date:  2012-08-05

9.  Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.

Authors:  Lina Y Dimberg; Anna Dimberg; Karolina Ivarsson; Mårten Fryknäs; Linda Rickardson; Gerard Tobin; Simon Ekman; Rolf Larsson; Urban Gullberg; Kenneth Nilsson; Fredrik Öberg; Helena Jernberg Wiklund
Journal:  BMC Cancer       Date:  2012-07-28       Impact factor: 4.430

10.  Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library.

Authors:  Ming-Szu Hung; Zhidong Xu; Yu-Ching Lin; Jian-Hua Mao; Cheng-Ta Yang; Pey-Jium Chang; David M Jablons; Liang You
Journal:  BMC Cancer       Date:  2009-05-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.